 Heparin
"Heparin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.
| Descriptor ID |
D006493
|
| MeSH Number(s) |
D09.698.373.400
|
| Concept/Terms |
Heparin- Heparin
- Unfractionated Heparin
- Heparin, Unfractionated
- Heparinic Acid
|
Below are MeSH descriptors whose meaning is more general than "Heparin".
Below are MeSH descriptors whose meaning is more specific than "Heparin".
This graph shows the total number of publications written about "Heparin" by people in this website by year, and whether "Heparin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 0 | 1 | 1 | | 1991 | 1 | 0 | 1 | | 1992 | 1 | 2 | 3 | | 1993 | 2 | 1 | 3 | | 1994 | 3 | 6 | 9 | | 1995 | 1 | 0 | 1 | | 1996 | 0 | 1 | 1 | | 1997 | 0 | 4 | 4 | | 1998 | 2 | 2 | 4 | | 2000 | 1 | 4 | 5 | | 2001 | 0 | 2 | 2 | | 2002 | 2 | 3 | 5 | | 2003 | 1 | 2 | 3 | | 2004 | 1 | 2 | 3 | | 2005 | 5 | 3 | 8 | | 2006 | 1 | 3 | 4 | | 2007 | 1 | 1 | 2 | | 2008 | 3 | 2 | 5 | | 2009 | 1 | 3 | 4 | | 2010 | 6 | 3 | 9 | | 2011 | 6 | 1 | 7 | | 2012 | 3 | 0 | 3 | | 2013 | 2 | 3 | 5 | | 2014 | 4 | 4 | 8 | | 2015 | 1 | 2 | 3 | | 2016 | 3 | 2 | 5 | | 2017 | 2 | 2 | 4 | | 2018 | 0 | 1 | 1 | | 2019 | 3 | 6 | 9 | | 2020 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Heparin" by people in Profiles.
-
Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, Dager WE, Deitelzweig SB, Ellsworth S, Garcia D, Kaatz S, Minichiello T. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. 2020 Jul; 50(1):72-81.
-
Hippensteel JA, LaRiviere WB, Colbert JF, Langouët-Astrié CJ, Schmidt EP. Heparin as a therapy for COVID-19: current evidence and future possibilities. Am J Physiol Lung Cell Mol Physiol. 2020 08 01; 319(2):L211-L217.
-
Park BD, Lyn-Kew K, Granchelli A, Mehta A. A 62-Year-Old Woman With Diffuse Myalgias, Fatigue, and Shortness of Breath. Chest. 2020 03; 157(3):e75-e78.
-
Raphael J, Mazer CD, Subramani S, Schroeder A, Abdalla M, Ferreira R, Roman PE, Patel N, Welsby I, Greilich PE, Harvey R, Ranucci M, Heller LB, Boer C, Wilkey A, Hill SE, Nuttall GA, Palvadi RR, Patel PA, Wilkey B, Gaitan B, Hill SS, Kwak J, Klick J, Bollen BA, Shore-Lesserson L, Abernathy J, Schwann N, Lau WT. Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. Anesth Analg. 2019 11; 129(5):1209-1221.
-
Shahi N, Phillips R, Meier M, Nehler M, Jacobs D, Recicar J, Bensard D, Moulton S. Anti-coagulation management in pediatric traumatic vascular injuries. J Pediatr Surg. 2020 Feb; 55(2):324-330.
-
Greenhawt M, Oppenheimer J, Shaker M. Fearing the Bark That Has No Bite: Parsing Practical From Theoretical Risk. Ann Allergy Asthma Immunol. 2019 10; 123(4):327-328.
-
West K, Janelle S, Schutz K, Hamilton S, Mayo K, Cichon MK, Nyquist AC, Bamberg WM, Dominguez SR. Outbreak of Serratia marcescens bacteremia in pediatric patients epidemiologically linked to pre-filled heparin flushes. Infect Control Hosp Epidemiol. 2019 10; 40(10):1201-1202.
-
Hambley BC, Norsworthy KJ, Jasem J, Zimmerman JW, Shenderov E, Webster JA, Showel MM, Gondek LP, Dalton WB, Prince G, Gladstone DE, Streiff MB, Pratz KW, Gojo I, Ghiaur G, Levis MJ, Smith BD, DeZern AE. Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction. Leuk Res. 2019 08; 83:106174.
-
Zhang X, Han X, Xia K, Xu Y, Yang Y, Oshima K, Haeger SM, Perez MJ, McMurtry SA, Hippensteel JA, Ford JA, Herson PS, Liu J, Schmidt EP, Linhardt RJ. Circulating heparin oligosaccharides rapidly target the hippocampus in sepsis, potentially impacting cognitive functions. Proc Natl Acad Sci U S A. 2019 05 07; 116(19):9208-9213.
-
Heizer JW, Schardt TQ, Murphy ME, Branchford BR. Unfractionated heparin dosing requirements in the presence of inflammation during the first six months of life. Thromb Res. 2019 May; 177:17-22.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|